FDA Orange Book
Generic for Eskalith CR
Eskalith CR contains lithium carbonate. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Eskalith CR is lithium carbonate. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Eskalith CR and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Eskalith CR products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, extended release, oral | 450MG | Discontinued | None | 3 | AB |
NDA 018152, held by JDS PHARMACEUTICALS LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic lithium carbonate
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| HIKMA PHARMACEUTICALS USA INC | 076691 | AB (A-rated, therapeutically equivalent) | January 5, 2004 | 450MG |
| GLENMARK PHARMACEUTICALS LTD | 091616 | AB (A-rated, therapeutically equivalent) | February 14, 2011 | 450MG |
| UNIQUE PHARMACEUTICAL LABORATORIES A DIV OF JB CHEMICALS AND PHARMACEUTICALS LTD | 205663 | AB (A-rated, therapeutically equivalent) | June 5, 2017 | 450MG |
Questions
Is there a generic for Eskalith CR?
Yes. The generic name for Eskalith CR is lithium carbonate. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Eskalith CR?
The active ingredient in Eskalith CR is lithium carbonate, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.